Amgen

Under CEO Robert A. Bradway, Amgen has balanced internal R&D with business development, sustained high cash conversion, and executed large‑scale manufacturing initiatives.

Leadership is advancing first‑in‑class assets (Imdelltra) and life‑cycle expansions (Lumakras combinations) while moving quickly on obesity (MariTide) with a dose‑titration strategy to address tolerability. Execution quality is generally strong, though pricing headwinds and large‑deal integration (Horizon) require continued discipline.